Ignite Creation Date:
2024-05-06 @ 7:43 PM
Last Modification Date:
2024-10-26 @ 3:13 PM
Study NCT ID:
NCT06118281
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-04-02
First Post:
2023-10-31
Brief Title:
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
Sponsor:
Novo Nordisk AS
Organization:
Novo Nordisk AS
Study Overview
Official Title:
ARTEMIS - Effects of Ziltivekimab Versus Placebo on Cardiovascular Outcomes in Patients With Acute Myocardial Infarction
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ARTEMIS
Brief Summary:
The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack Ziltivekimab might reduce development of heart disease thereby preventing new heart attacks or strokes Participants will either get ziltivekimab active medicine or placebo a dummy medicine which has no effect on the body Which treatment participants get is decided by chance The chance of getting ziltivekimab or placebo is the same Ziltivekimab is not yet approved in any country or region in the world It is a new medicine that doctors cannot prescribe The study will last for about 2 years
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2023-506876-28 | OTHER | European Medical Agency EMA | None |
| U1111-1294-3473 | OTHER | None | None |